NYSEAMERICAN:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $0.13 -0.01 (-8.77%) Closing price 04:10 PM EasternExtended Trading$0.13 +0.00 (+2.29%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About AIM ImmunoTech Stock (NYSEAMERICAN:AIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AIM ImmunoTech alerts:Sign Up Key Stats Today's Range$0.13▼$0.1550-Day Range$0.13▼$0.2352-Week Range$0.12▼$1.88Volume645,253 shsAverage Volume10.55 million shsMarket Capitalization$3.99 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company Overview AIM ImmunoTech is a biotechnology company focused on developing treatments that activate or modulate the immune system. Its work centers on Ampligen (rintatolimod), an investigational drug designed to stimulate immune responses and studied in clinical research for conditions including myalgic encephalomyelitis/chronic fatigue syndrome and certain cancers. The company also has rights to Alferon N, a natural interferon product approved in the United States for a specific use in patients with recurrent or refractory external genital warts. AIM’s activities include research and development, clinical testing, and potential commercialization of its products. Previously known as Hemispherx Biopharma, the company adopted the AIM ImmunoTech name in 2019. Its development and regulatory activities have principally been conducted in the United States, with research programs also involving international collaborators.AI Generated. May Contain Errors. Read More AIM ImmunoTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreAIM MarketRank™: 3.198198198195 of 5 starsAIM ImmunoTech scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAIM ImmunoTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialAIM ImmunoTech has a consensus price target of $9.00, representing about 6,770.2% upside from its current price of $0.13.Amount of Analyst CoverageAIM ImmunoTech has received no research coverage in the past 90 days.Read more about AIM ImmunoTech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AIM ImmunoTech are expected to grow in the coming year, from ($0.78) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AIM ImmunoTech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIM ImmunoTech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.32% of the float of AIM ImmunoTech has been sold short.Short Interest Ratio / Days to CoverAIM ImmunoTech has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AIM ImmunoTech has recently decreased by 7.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.16 News SentimentAIM ImmunoTech has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for AIM ImmunoTech this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $42,522.00 in company stock, which represents 1.0663% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $42,522.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.82% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by Institutions12.02% of the stock of AIM ImmunoTech is held by institutions.Read more about AIM ImmunoTech's insider trading history. Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIM Stock News HeadlinesPancreatic cancer drug Ampligen readout cannot separate it from Durvalumab, trial design showsNovember 13 at 5:16 PM | msn.comAIM ImmunoTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13 at 12:15 PM | marketscreener.comMYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 16 at 1:00 AM | Profits Run (Ad)AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial ResultsNovember 13 at 8:30 AM | globenewswire.comAIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesNovember 10, 2026 | globenewswire.comAIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic CancerNovember 5, 2026 | globenewswire.comAIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysOctober 7, 2026 | finance.yahoo.comAIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysOctober 7, 2026 | globenewswire.comSee More Headlines AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $1.1289 at the start of the year. Since then, AIM stock has decreased by 88.4% and is now trading at $0.1310. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.12. The business had revenue of $22 thousand for the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 789.11% and a negative net margin of 15,526.38%. When did AIM ImmunoTech's stock split? AIM ImmunoTech shares reverse split on the morning of Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Tesla (TSLA), NIO (NIO), Nokia (NOK), Vaxart (VXRT), FuelCell Energy (FCEL), iBio (IBIO) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/12/2026Today11/16/2026AGM 202611/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:AIM Previous SymbolNYSEAMERICAN:HEB CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees21Year Founded1990Price Target and Rating Average Price Target for AIM ImmunoTech$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+6,770.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($24.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.96 million Net Margins-15,526.38% Pretax Margin-15,526.38% Return on Equity-789.11% Return on Assets-153.37% Debt Debt-to-Equity RatioN/A Current Ratio2.75 Quick Ratio2.75 Sales & Book Value Annual Sales$90 thousand Price / Sales44.31 Cash FlowN/A Price / Cash FlowN/A Book Value($2.99) per share Price / Book-0.04Miscellaneous Outstanding Shares30,440,000Free Float30,192,000Market Cap$3.99 million OptionableNot Optionable Beta1.32 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSEAMERICAN:AIM) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.